The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.62
Bid: 42.60
Ask: 42.68
Change: 1.00 (2.40%)
Spread: 0.08 (0.188%)
Open: 42.28
High: 42.70
Low: 42.12
Prev. Close: 41.62
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Development Update

16 Mar 2022 07:00

RNS Number : 8969E
Assura PLC
16 March 2022
 

16 March 2022

Assura plc

Development update

Assura plc ("Assura"), the leading primary care property investor and developer, is pleased to announce it has reached financial close on the Northumbria Health and Care Academy, a £25 million development in Cramlington, Northumberland.

The building will be primarily let to Northumbria Healthcare NHS Foundation Trust on a 30-year effective FRI lease with rent reviewed annually by reference to RPI.

Situated on undeveloped land on the site of Northumbria Specialist Emergency Care Hospital, the Academy will house a training centre of excellence and clinical space for delivery of a range of community health services as well as conference and administrative space. The training centre will initially focus on nursing, midwifery and allied health professional training.

In accordance with Assura's existing targets, the Academy is expected to achieve a BREEAM rating of Excellent and an EPC of A.

In addition, the Academy is aiming to become the UK's first Gold accredited healthcare sector building under the IWBI WELL Building Standard. WELL certification is aimed at improving health and human experience through design, focusing on 10 concepts including air, water, light, thermal comfort and community.

The project will also be a flagship for Assura's social impact programme, working with the NHS Trust community engagement programme on local arts projects, and contributing towards the delivery of a hospital nature trail designed to promote staff wellbeing.

The Academy is expected to have an 18-month build period with completion by Q4 2023.

Current development activity

Since the last trading update as at 31 December 2021, Assura has moved on site with two new development schemes (including the centre referenced above).

Assura is now on site with 16 developments with a total development cost of £128 million (December 2021: 14, £97 million).

Jonathan Murphy, CEO, said:

"Working with the Northumbria Healthcare NHS Foundation Trust, we know this Academy in Cramlington will make a real difference to people in the area.

"This scheme further demonstrates our strategy in action expanding our offering, working with NHS Trusts to develop high-quality and thoughtfully designed buildings that facilitate better health provision for their community, and helping deliver positive sustainability and social impact outcomes."

- ENDS -

 

For more information, please contact:

Assura plc

David Purcell, Head of Investor Relations

Tel: 01925 945354

Email: Investor@assura.co.uk

Finsbury

Gordon SimpsonJames Thompson

Tel: 0207 251 3801

Email: Assura@finsbury.com

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2021, Assura's property portfolio was valued at £2,595 million.

 

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

Assura plc LEI code: 21380026T19N2Y52XF72

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUQCWUPPPGA
Date   Source Headline
1st May 20242:30 pmRNSHolding(s) in Company
1st May 20247:00 amRNSNotice of Year End Results
30th Apr 20247:00 amRNSTotal Voting Rights
16th Apr 20247:40 amRNSDirector/PDMR Shareholding
8th Apr 20244:34 pmRNSDirector/PDMR Shareholding
8th Apr 20247:00 amRNSScrip Dividend Declaration
22nd Mar 20242:18 pmRNSHolding(s) in Company
14th Mar 20248:30 amRNSScrip Calculation Price
6th Mar 20241:26 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSNotice of Dividend
8th Feb 20242:00 pmRNSCapital Markets Event
7th Feb 20242:33 pmRNSDirector/PDMR Shareholding
1st Feb 20249:32 amRNSTotal Voting Rights
16th Jan 20248:26 amRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSTrading Update
9th Jan 20248:59 amRNSDirector/PDMR Shareholding
8th Jan 20247:00 amRNSScrip Dividend Declaration
21st Dec 20234:20 pmRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSScrip Calculation Price
6th Dec 20232:57 pmRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSNotice of Dividend
16th Nov 20237:00 amRNSAssura Plc Interim Results
8th Nov 20232:32 pmRNSDirector/PDMR Shareholding
1st Nov 20237:00 amRNSAppointment of Board Fellow
31st Oct 20237:00 amRNSNotice of Interim Results
31st Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20232:04 pmRNSDirector/PDMR Shareholding
9th Oct 202311:13 amRNSDirector/PDMR Shareholding
9th Oct 20238:11 amRNSScrip Dividend Declaration
9th Oct 20237:00 amRNSRefinancing of RCF & new sustainability linkage
9th Oct 20237:00 amRNSTrading Update
18th Sep 20239:51 amRNSVesting and sale of restricted shares
14th Sep 20239:20 amRNSScrip Calculation Price
31st Aug 20237:00 amRNSNotice of Dividend
24th Aug 20238:36 amRNSHolding(s) in Company
8th Aug 20235:05 pmRNSDirector/PDMR Shareholding
31st Jul 20239:57 amRNSTotal Voting Rights
24th Jul 20237:00 amRNSDevelopment update
14th Jul 20231:47 pmRNSDirector/PDMR Shareholding
13th Jul 20234:47 pmRNSExercise of Nil Cost Options under PSP
12th Jul 20234:36 pmRNSDirector/PDMR Shareholding
10th Jul 202312:38 pmRNSHolding(s) in Company
10th Jul 20239:20 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSScrip Dividend Declaration & Additional Listing
6th Jul 20232:47 pmRNSResult of AGM
6th Jul 202312:28 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSTrading Update
3rd Jul 20237:00 amRNSChange of Registered Office
29th Jun 20234:46 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSCompletion of 100th development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.